The challenge of developing human 3D organoids into medicines
Vives Armengol, Joaquim (Universitat Autònoma de Barcelona. Departament de Medicina)
Batlle Morera, Laura (Centre de Regulació Genòmica)

Data:	2020
Resum:	The capacity of organoids to generate complex 3D structures resembling organs is revolutionizing the fields of developmental and stem cell biology. We are currently establishing the foundations for translational applications of organoids such as drug screening, personalized medicine and launching the future of cell therapy using organoids. However, clinical translation of organoids into cell replacement therapies is halted due to (A) a few preclinical studies demonstrating their efficacy and (B) the lack of robust, reproducible, and scalable methods of production in compliance with current pharmaceutical standards. In this issue of Stem Cell Research & Therapy [ref], Dossena and collaborators present a validated bioprocess design for large-scale production of human pancreatic organoids from cadaveric tissue in accordance with current good manufacturing practice. The authors also propose a set of specifications of starting materials and critical quality attributes of final products that are of interest to other developments provided that this type of medicines are different than any other medicinal product due to their complex composition and living nature of the active ingredient. Although large-scale production of functional cells secreting insulin is still a challenge, the development of methods such as the one presented by Dossena and collaborators contributes to move toward clinical use of organoids in the treatment of type 1 diabetes and opens avenues for future clinical use of organoids in degenerative pathologies.
Ajuts:	Instituto de Salud Carlos III PI19/01788 Ministerio de Economía y Competitividad RD16/0011/0028 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017-SGR-719
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Good manufacturing practice ; Organoid ; Pancreas ; Regenerative medicine ; Tissue engineering ; Regulatory and quality compliance
Publicat a:	Stem cell research & therapy, Vol. 11 (march 2020) , ISSN 1757-6512

DOI: 10.1186/s13287-020-1586-1
PMID: 32127036

4 p, 267.0 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats